Follicular lymphoma is a B-cell non-Hodgkin lymphoma arising from cells related to those of the germinal centers of lymphoid follicles. It most often affects lymph nodes, but frequently also involves the bone marrow, spleen, and other tissues. The name refers to the follicle-like arrangements formed by the malignant cells, not to hair follicles. Most conventional cases grow relatively slowly, although their behavior varies considerably and some transform into an aggressive lymphoma.
The disease is among the most common indolent lymphomas in adults. Many people have widespread disease when it is discovered, yet may remain well for years. Management therefore differs from that of many other cancers: selected asymptomatic patients undergo active surveillance, localized disease may be treated with potentially curative radiotherapy, and symptomatic advanced disease is usually treated with systemic therapy. Modern treatment can produce prolonged remissions, but conventional advanced-stage follicular lymphoma generally follows a relapsing course. Its classification, molecular biology, tumor burden, and response to treatment all contribute to understanding an individual disease course.
Definition, classification, and historical development
Follicular lymphoma belongs to the mature B-cell neoplasms, a group of cancers derived from lymphocytes that have passed through early development. Its cells resemble those normally found in the germinal center, where activated B cells proliferate and refine their antibody responses. Conventional tumors contain varying proportions of small, cleaved cells called centrocytes and larger cells called centroblasts. The characteristic growth pattern consists of closely packed abnormal follicles that replace normal lymph-node architecture, although diffuse areas can coexist.
Descriptions of a nodular lymphoid malignancy appeared in the 1920s, including reports by Nathan Brill and colleagues in 1925 and Douglas Symmers in 1927. Older terminology, including “giant follicular lymphoblastoma” and “nodular lymphoma,” preceded modern classifications based on cell lineage and immunophenotype. The introduction of immunologic techniques, chromosome analysis, and molecular testing established follicular lymphoma as a germinal-center B-cell neoplasm rather than simply a tumor defined by its microscopic pattern.
Traditional grading counts centroblasts in representative microscopic fields. Grades 1 and 2 contain fewer large cells and are commonly considered together clinically. Grade 3A contains more centroblasts but retains centrocytes, whereas grade 3B consists of follicles composed of large transformed cells without the usual centrocytic component. Grading has limitations because different areas of one tumor can differ and observers may classify borderline samples differently. A small tissue sample can therefore underrepresent the biologically important parts of a lesion.
Contemporary classification systems do not use entirely identical terminology. The fifth edition of the World Health Organization classification groups most former grades 1, 2, and 3A within classic follicular lymphoma and makes grading of this category optional. It uses “follicular large B-cell lymphoma” for the entity corresponding broadly to former grade 3B. The 2022 International Consensus Classification retains the traditional grading framework. Consequently, a report’s classification system and descriptive findings matter more than a grade interpreted in isolation.
Several distinct entities must be separated from conventional adult nodal disease. Pediatric-type follicular lymphoma often presents as localized head-and-neck lymphadenopathy in children or young adults and typically lacks the characteristic BCL2 rearrangement. Duodenal-type follicular lymphoma usually involves the intestinal mucosa and often has a particularly indolent course. Primary cutaneous follicle center lymphoma is a separate skin lymphoma, not merely nodal follicular lymphoma occurring in the skin. These distinctions affect staging, prognosis, and the interpretation of treatment studies.
Epidemiology and factors associated with risk
The epidemiology of follicular lymphoma varies geographically. It accounts for approximately one fifth of non-Hodgkin lymphomas in many North American and Western European series, but represents a smaller proportion in several Asian populations. Comparisons depend on population age, registry coverage, diagnostic practice, and the classification system used. Population-based registries in the United States generally place its annual incidence in the range of a few cases per 100,000 people.
Follicular lymphoma is predominantly a disease of middle-aged and older adults, with diagnosis commonly occurring around the sixth or seventh decade of life. It is uncommon in children, whose follicular lymphomas more often belong to distinct pediatric-type categories. Both sexes are affected. Reported differences between population groups are not adequately explained by a single genetic or environmental factor, and differences in health-care access and ascertainment complicate interpretation.
Most affected individuals have no identifiable cause. A family history of non-Hodgkin lymphoma is associated with increased risk, and inherited variation in immune-related genomic regions contributes to susceptibility. However, familial clustering does not usually follow a simple single-gene inheritance pattern. Having an affected relative does not mean that follicular lymphoma will develop, and familial risk accounts for only a minority of cases.
Studies have investigated agricultural chemicals, occupational exposures, smoking, body size, and immune-related conditions. Some associations have been reported, but their consistency and specificity vary. Unlike several other lymphomas, conventional follicular lymphoma has no established single infectious cause. It is not an infection and is not transmitted between people. It should also not be assumed to share the same causal relationships with immunodeficiency or viruses as all other forms of lymphoma.
A notable epidemiologic observation is that very small populations of B cells carrying the characteristic rearrangement can be detected in some healthy adults. Their frequency tends to increase with age, and only a small fraction of people carrying such cells develop lymphoma. This supports a multistep model in which an initiating genetic event is insufficient by itself. Additional changes in the abnormal cell and its tissue environment are required for clinically apparent disease.
There is no established population screening program for follicular lymphoma. Its relatively low incidence, variable natural history, and the presence of precursor-like molecular findings in healthy people make screening fundamentally different from confirming lymphoma in someone with an abnormal lymph node. Incidence figures also should not be confused with prevalence: because many affected people live for years, the number living with the disease is substantially greater than the number newly diagnosed in a single year.
Molecular origins and the tumor microenvironment
Normal germinal-center B cells undergo repeated cycles of proliferation, antibody-gene modification, and selection. These processes generate effective antibodies but also create opportunities for harmful alterations in DNA. Follicular lymphoma exploits this developmental program. Its malignant cells commonly retain germinal-center markers and evidence of somatic hypermutation, the process through which antibody genes normally acquire sequence changes during an immune response.
The best-known genetic feature is the chromosomal translocation , present in most conventional cases. It brings the BCL2 gene on chromosome 18 under the influence of regulatory elements associated with the immunoglobulin heavy-chain locus on chromosome 14. The resulting excess BCL2 protein inhibits apoptosis, or programmed cell death. Cells that would ordinarily be eliminated can consequently survive. This alteration primarily promotes survival rather than functioning as a complete explanation for uncontrolled tumor growth.
Additional mutations accumulate during disease development. Frequently affected genes include KMT2D, CREBBP, EZH2, and EP300, which regulate chromatin structure and gene expression. Changes in these genes can alter germinal-center differentiation, antigen presentation, and the accessibility of DNA to transcriptional machinery. Activating EZH2 mutations are especially relevant because EZH2 is a component of a protein complex that modifies histones, and pharmacologic inhibition of this enzyme has become a treatment strategy in selected relapsed disease.
Follicular lymphoma is not simply a uniform mass of genetically identical cells. A tumor can contain multiple related subclones, and different anatomical sites may contain different proportions of those subclones. Treatment can suppress sensitive populations while resistant populations persist. Studies comparing diagnostic and transformed tumors indicate that aggressive transformation may emerge from a shared ancestral population rather than always developing through a simple linear progression from the dominant original clone.
The surrounding tissue is also biologically active. Follicular dendritic cells, stromal cells, macrophages, and different T-cell populations provide signals that affect malignant-cell survival and immune recognition. Chemokines help organize cells within follicles, while interactions between tumor cells and immune cells can support growth or restrain it. This tumor microenvironment helps explain why tissue architecture and nonmalignant cells contain information not captured by sequencing tumor DNA alone.
These observations also clarify the distinction between a molecular precursor and an established malignancy. In situ follicular B-cell neoplasm consists of abnormal BCL2-positive germinal-center cells within otherwise preserved follicles. It may be found incidentally and is not equivalent to overt, architecturally destructive follicular lymphoma. The transition from precursor-like populations to clinically significant disease involves combinations of genetic evolution, altered tissue interactions, and expansion across anatomical sites.
Clinical presentation and patterns of involvement
The most frequent presentation is persistent, usually painless enlargement of peripheral lymph nodes. Cervical, axillary, and inguinal nodes may be involved, often at several sites. Enlargement can fluctuate, and occasional partial spontaneous regression does not exclude lymphoma. Because the disease often grows slowly, lymphadenopathy may have been present for months before a diagnostic evaluation establishes its cause.
Deep lymph nodes can enlarge without producing a visible lump. Abdominal or pelvic disease may cause fullness, discomfort, early satiety, or compression of nearby structures. An enlarged spleen can contribute to abdominal symptoms and reduced blood-cell counts. Disease in the chest can occasionally produce cough or shortness of breath. Symptoms depend on anatomical location and tumor burden rather than on lymphoma subtype alone.
Systemic symptoms include unexplained fever, drenching night sweats, and unintentional weight loss. In lymphoma staging terminology, these are called B symptoms; the conventional weight-loss threshold is more than 10% of body weight over six months. Fatigue is common but is not itself a B symptom. Many patients with advanced follicular lymphoma have none of these manifestations, illustrating why extensive anatomical involvement does not necessarily imply immediate physiological instability.
Bone-marrow involvement is frequent in conventional advanced disease. It may be clinically silent or contribute to anemia, thrombocytopenia, or reduced white-cell counts. Cytopenias can also arise from splenic sequestration, immune mechanisms, treatment effects, or unrelated conditions, so their cause requires interpretation rather than automatic attribution to marrow replacement. Lymphoma cells sometimes circulate in the blood, but a leukemic presentation does not by itself change the diagnosis to a separate leukemia.
Extranodal involvement can affect the gastrointestinal tract, skin, liver, and other organs. Gastrointestinal follicular lymphoma may be discovered incidentally during endoscopy, particularly in the duodenum. Localized duodenal-type disease differs clinically from widespread nodal lymphoma secondarily involving the bowel. Similarly, lymphoma detected in skin requires distinction between systemic involvement and a primary cutaneous lymphoma.
A change in the established clinical pattern can indicate a biologically different process. Rapid enlargement of one mass, new severe symptoms, rising lactate dehydrogenase, or new involvement of an unusual site may raise concern for transformation. None of these findings proves transformation: infection, another cancer, or progression without transformation can produce similar changes. Tissue examination remains important because clinically similar presentations can require very different treatment approaches.
Tissue diagnosis and differential diagnosis
A definitive diagnosis usually requires a tissue biopsy that permits assessment of both cellular appearance and architecture. Excision of an accessible lymph node often provides the most complete material. A sufficiently large core-needle biopsy can establish the diagnosis when excision is impractical, but small samples may miss diffuse large-cell areas or fail to distinguish partial involvement from a different lymphoid process. Fine-needle aspiration alone generally cannot provide all the architectural information needed for initial classification.
On histopathologic examination, conventional follicular lymphoma typically shows crowded follicles with reduced polarization, attenuated mantle zones, and fewer tingible-body macrophages than reactive germinal centers. Centrocytes have irregular or cleaved nuclei, while centroblasts are larger and contain prominent nucleoli. The follicles may occupy most of a lymph node, and tumor can extend into surrounding tissue. Marrow involvement often forms aggregates adjacent to bony trabeculae, although other patterns occur.
Immunohistochemistry usually demonstrates B-cell markers such as CD20 and PAX5, together with the germinal-center-associated proteins CD10 and BCL6. BCL2 expression within abnormal follicles is particularly useful because normal reactive germinal-center B cells generally lack strong BCL2 expression. Nevertheless, no single stain establishes the diagnosis. Some genuine follicular lymphomas lack CD10 or BCL2 expression, and other lymphomas can share parts of the same immunophenotype.
Flow cytometry can identify a clonal B-cell population through light-chain restriction and characterize its surface markers. Fluorescence in situ hybridization or other molecular methods can detect a BCL2 rearrangement and investigate selected alternative alterations. These techniques supplement morphology rather than replace it. A positive molecular finding in isolation does not establish the extent of disease or distinguish all precursor lesions from overt lymphoma.
The differential diagnosis includes reactive follicular hyperplasia, nodal marginal zone lymphoma with follicular colonization, mantle cell lymphoma, and other mature B-cell neoplasms. Mantle cell lymphoma is commonly distinguished by cyclin D1 expression or a CCND1 rearrangement, often together with CD5 positivity. Reactive follicles generally preserve normal organization and contain a mixed, nonclonal B-cell population. Large-cell morphology raises the possibility of follicular large B-cell lymphoma or a diffuse aggressive component.
Clinicopathologic correlation is essential in unusual cases. Age, anatomical distribution, staging findings, and molecular features help separate pediatric-type, duodenal-type, and other variants from conventional nodal disease. If the clinical course changes substantially, a new biopsy can answer a different question from the original specimen: whether the present disease remains indolent follicular lymphoma or has transformed into an aggressive lymphoma.
Staging, tumor burden, and prognostic assessment
Staging describes where lymphoma is present, whereas prognostic assessment estimates aspects of its likely course. The Ann Arbor framework, incorporated into modern Lugano recommendations, distinguishes a single involved nodal region in stage I, multiple nodal regions on one side of the diaphragm in stage II, nodal disease on both sides in stage III, and disseminated extranodal involvement in stage IV. Bone-marrow involvement generally establishes stage IV. Unlike stage IV in many solid tumors, stage IV follicular lymphoma can remain compatible with prolonged survival.
Baseline assessment commonly includes a medical history, physical examination, complete blood count, and biochemical testing, including lactate dehydrogenase. Renal and liver function help characterize organ involvement and the feasibility of particular treatments. Additional investigations are determined by the disease pattern and contemplated therapy. Testing for infections such as hepatitis B is relevant before B-cell-depleting treatment because viral reactivation is a recognized complication.
Fluorodeoxyglucose positron emission tomography combined with computed tomography, or PET/CT, is important for staging most follicular lymphomas because they are usually metabolically active on this imaging method. It can reveal unsuspected disease and identify a suitable biopsy target when transformation is suspected. However, high tracer uptake does not itself prove transformation. Bone-marrow biopsy may still provide information that PET/CT does not reliably exclude in indolent lymphoma.
The Follicular Lymphoma International Prognostic Index, published in 2004, assigns one adverse factor each for age over 60 years, stage III or IV, hemoglobin below 12 g/dL, elevated lactate dehydrogenase, and involvement of more than four nodal areas. The total separates patients into risk groups. FLIPI was developed for population-level prognostic stratification; it neither specifies an individual life expectancy nor independently determines whether treatment is necessary.
Other systems address different settings. FLIPI2 incorporates age, hemoglobin, marrow involvement, beta-2 microglobulin, and the size of the largest involved node. Molecular models such as m7-FLIPI combine clinical factors with mutations, but their usefulness depends on the population and treatment studied. Such models have not replaced clinical judgment or routine pathology.
Tumor burden is assessed separately from stage. Groupe d’Étude des Lymphomes Folliculaires, or GELF, criteria incorporate findings such as a mass larger than 7 cm, multiple substantially enlarged nodal sites, systemic symptoms, clinically important cytopenias, effusions, or threatened organ function. A patient can have stage IV disease but low tumor burden, while another with less anatomically extensive disease may need treatment because a mass compresses a vital structure.
Localized disease and active surveillance
A minority of patients have genuinely localized follicular lymphoma after complete staging. For stage I and selected contiguous stage II disease, involved-site radiotherapy can produce durable disease control and may be curative. This is an important exception to the usual description of follicular lymphoma as a chronic relapsing disease. Accurate staging matters because disease outside the planned radiation field changes both the treatment objective and the likelihood of sustained control from local treatment alone.
Modern involved-site radiotherapy treats the initially affected region with margins adapted to imaging and anatomy rather than the extensive fields used historically. A dose around 24 Gy in multiple fractions is a standard definitive approach for indolent lymphoma. Very-low-dose radiotherapy, commonly 4 Gy in two fractions, can provide useful local palliation, but randomized evidence has shown less durable local control than 24 Gy when long-term local control is the principal objective. Radiation effects depend on the site treated and the organs receiving exposure.
Localized disease does not always receive radiotherapy alone. Tumor bulk, symptoms, suspected occult dissemination, anatomical constraints, and pathological subtype influence the approach. Some studies have examined adding anti-CD20 treatment or systemic therapy to radiation. Differences in progression-free survival do not automatically establish an overall-survival advantage, particularly in a disease with effective treatments at relapse. Selected completely excised lesions or special clinicopathological variants may also be managed differently from typical nodal disease.
For asymptomatic advanced-stage disease with low tumor burden, active surveillance—also called watchful waiting—is an established strategy. It consists of planned clinical review and reassessment rather than an assumption that the lymphoma is harmless. Historical randomized studies found no overall-survival advantage from immediately treating all asymptomatic patients with older cytotoxic regimens. This supported delaying therapy until there was a clinical indication, thereby avoiding treatment toxicity during a period when treatment might not improve how the patient feels or functions.
Anti-CD20 antibody treatment has also been studied in asymptomatic low-burden disease. Rituximab can delay the need for subsequent treatment compared with observation, but this is a different outcome from demonstrating that everyone lives longer with immediate therapy. The choice between observation and early antibody treatment therefore involves distinct endpoints, treatment exposure, and patient circumstances rather than a simple treated-versus-untreated division.
During surveillance, treatment may become appropriate because of symptomatic or bulky progression, impaired blood-cell production, threatened organ function, troublesome effusions, or other clinically important disease effects. A change in behavior may instead prompt biopsy for suspected transformation. The duration of observation varies widely: some patients need treatment relatively soon, while others remain untreated for many years.
Systemic treatment of symptomatic disease
When advanced follicular lymphoma requires systemic treatment, the objective is usually to control symptoms, reduce tumor burden, and obtain a durable remission while limiting immediate and cumulative toxicity. Treatment selection reflects pathology, tumor burden, comorbidity, prior therapy, and the possibility of transformation. Conventional grades 1–2 and many grade 3A cases are generally approached as indolent lymphoma, whereas follicular large B-cell lymphoma, formerly grade 3B, is commonly managed along aggressive-lymphoma principles.
Anti-CD20 monoclonal antibodies are central to treatment. Rituximab and obinutuzumab bind CD20 on B cells and promote their elimination through immune-mediated mechanisms. They are not specific only to malignant B cells, which explains both their therapeutic effects and some adverse consequences. Infusion reactions, reduced immunoglobulin levels, and infection risk are clinically relevant. Hepatitis B reactivation is a well-established concern with this class.
Common initial regimens combine an anti-CD20 antibody with chemotherapy, including bendamustine, CHOP, or CVP. CHOP contains cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP omits doxorubicin. These regimens differ in the depth and duration of immune suppression, effects on blood counts, neuropathy, and cardiac toxicity. Doxorubicin-containing treatment is particularly relevant when an aggressive component is present, although selection cannot be inferred from stage alone.
A chemotherapy-free systemic option combines rituximab with lenalidomide, an immunomodulatory drug. Its activity depends partly on effects on immune cells and their interaction with malignant B cells rather than solely on direct cytotoxicity. Comparative trials have shown that this approach can provide substantial disease control, but it has its own adverse-effect profile, including cytopenias, rash, and thrombotic risk. “Chemotherapy-free” therefore does not mean free of significant treatment toxicity.
Maintenance anti-CD20 therapy can extend progression-free survival after successful induction in appropriate settings. In the PRIMA trial, two years of rituximab maintenance improved the duration of disease control after first-line immunochemotherapy, without demonstrating an overall-survival advantage in long-term follow-up. Maintenance also increases cumulative treatment exposure and can affect infection risk and immune recovery. The results illustrate the importance of distinguishing remission duration from survival.
Response assessment integrates symptoms, examination, laboratory results, and imaging, commonly using PET-based criteria. A complete metabolic response is a favorable finding but does not prove eradication of every malignant cell. Residual masses may represent inactive tissue, while a new metabolically active lesion can have causes other than lymphoma. Biopsy is particularly important when an unexpected finding would substantially change the treatment strategy.
Relapsed disease, transformation, and newer therapies
Relapse means that lymphoma has returned after a response; refractory disease fails to respond adequately or progresses during treatment. Both situations are heterogeneous. A small, asymptomatic recurrence after a long remission may be observed, while rapidly progressive or organ-threatening disease requires a different approach. Reassessment considers the duration of the previous response, prior toxicities, current tumor distribution, and whether the histology has changed.
Transformation most commonly produces diffuse large B-cell lymphoma. Historical series often estimated an annual transformation risk around 2–3%, although estimates vary with follow-up, biopsy practices, treatment era, and competing events. Transformation is established by tissue findings, not by rapid growth or a high PET uptake value alone. Its treatment generally follows aggressive-lymphoma strategies, with the specific regimen influenced by previous exposure to anthracyclines and other drugs.
Relapsed indolent disease may respond to another anti-CD20-based regimen, lenalidomide combinations, or selected targeted therapies. Tazemetostat inhibits EZH2 and has activity in previously treated follicular lymphoma, including tumors with activating EZH2 mutations. The clinical role of a targeted agent depends not only on its response rate but also on response duration, toxicity, available alternatives, and regulatory indication. Several PI3K inhibitors previously used or studied in this setting encountered important safety concerns and withdrawals of indications, illustrating why treatment lists change over time.
CD20-by-CD3 bispecific antibodies bring malignant B cells into contact with T cells. Agents including mosunetuzumab and epcoritamab have entered clinical use for previously treated follicular lymphoma in some jurisdictions. Their administration commonly uses step-up dosing to reduce early immune toxicity. Cytokine release syndrome, infections, and cytopenias are important adverse effects; neurologic toxicity can also occur. These agents differ in schedule, route, and whether treatment has a fixed or continuing duration.
CAR T-cell therapy uses genetically modified T cells directed against a B-cell antigen, usually CD19. Products including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have shown substantial activity in multiply treated follicular lymphoma and have received approvals in particular settings. Treatment requires cell collection, manufacturing, preparative therapy, and specialized monitoring. Cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, prolonged cytopenias, and infection are among its major risks.
Hematopoietic stem-cell transplantation remains relevant for selected patients. Autologous transplantation can consolidate a response in some high-risk relapsed settings. Allogeneic transplantation can produce a graft-versus-lymphoma effect, but carries substantial risks, including graft-versus-host disease and treatment-related mortality. Its role has narrowed as effective antibody-based and cellular treatments have expanded.
Prognosis, long-term effects, and disease monitoring
Follicular lymphoma has a highly variable natural history. Many patients live for well over a decade, and survival has improved substantially since anti-CD20 antibodies became widely available. Population estimates nevertheless combine people with very different ages, disease burdens, pathological variants, and treatments. Relative survival, overall survival, and lymphoma-specific survival answer different questions and should not be treated as interchangeable measures.
The timing of progression is informative. Progression of disease within 24 months after first-line immunochemotherapy, commonly termed POD24, identifies a group with poorer subsequent outcomes than patients without early progression. It is a clinical risk marker, not a separate pathological diagnosis, and it does not establish that transformation has occurred. The exact definition and prognostic performance depend on when the time interval starts and on the treatment setting in which the measure is applied.
Long-term morbidity can come from both lymphoma and its treatment. Repeated B-cell-depleting therapy can cause prolonged impairment of antibody responses. Chemotherapy can contribute to infertility, neuropathy, cardiac injury, or therapy-related myeloid neoplasms, depending on the agents and cumulative exposure. Infection may result from the underlying disease, reduced immunoglobulins, lymphocyte depletion, or neutropenia. These risks vary substantially between regimens and between individuals.
Follow-up focuses on symptoms, physical findings, blood counts, treatment effects, and evidence of clinically meaningful recurrence. Repeated imaging can detect abnormalities but also exposes patients to radiation and incidental findings; finding relapse earlier on a scan does not necessarily improve survival. PET/CT is therefore not simply a permanent routine surveillance test after every remission. Imaging is interpreted in relation to the clinical question, such as unexplained symptoms or possible transformation.
The burden of a chronic relapsing cancer also includes disrupted work, financial effects, uncertainty, fatigue, and changes in health-related quality of life. These outcomes may not closely track tumor size or progression-free survival. Patient-reported outcomes in clinical trials help measure effects that laboratory results and imaging cannot capture. Palliative care addresses symptom burden and quality of life and can accompany disease-directed treatment rather than being restricted to the last phase of illness.
Research increasingly examines whether circulating tumor DNA, molecular response measurements, and tissue-based immune signatures can improve risk assessment. Detectable residual molecular disease may anticipate relapse in some settings, but assay sensitivity, sampling methods, and the consequences of acting on a result remain important limitations. A test becomes clinically useful only when its information reliably improves a relevant decision or outcome; an association with future progression is not by itself sufficient.